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Objective: Toupdateapublishedmeta-analysis ofdouble-blindplacebo-controlled randomizedclinical trials
(RCTs) to assess the efﬁcacyof chondroitin sulfate as a structure-modifying drug for kneeosteoarthritis (OA).
Design: A published meta-analysis of randomized controlled trials was updated to include data from one
new trial and ﬁnal data from a second trial both published recently in peer-reviewed literature. This
meta-analysis was limited to three RCTs of 2-year duration. Data were pooled using a ﬁxed effects model
as there was no evidence of important heterogeneity.
Results: Pooled results demonstrated a small signiﬁcant effect of chondroitin sulfate on the reduction in
rate of decline in minimum joint space width of 0.13 mm [95% conﬁdence interval (CI) 0.06, 0.19]
(P¼ 0.0002) that corresponded to an effect size of 0.23 (95% CI 0.11, 0.35) (P¼ 0.0001).
Conclusion: These results demonstrate that chondroitin sulfate is effective for reducing the rate of decline
in minimum joint space width in patients with knee OA.
 2010 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Guidelines for the management of patients with osteoarthritis
(OA) of the knee recommend a combination of non-pharmacologic
and pharmacologic modalities with the goals of relieving pain and
improving functional limitation and health-related quality of
life1e4. An additional goal of therapy is limiting the progression of
joint damage, often referred to as structure modiﬁcation. The rate
of joint space narrowing, a variable derived from serial measure-
ments of joint space width, is currently the accepted biomarker for
structural progression for purposes of design and conduct of
randomized clinical trials (RCTs) for registration of products in both
the United States and Europe5. Presently, there are no products
approved either by the Food and Drug Administration in the United
States or the European Medicines Agency in Europe for the indi-
cation of slowing the decline in minimum joint space width in
patients with OA of the knee.
Chondroitin sulfate is a sulfated glycosaminoglycan, composed of
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that is incorporated into aggrecan molecules during synthesis by
chondrocytes. Meta-analyses of randomized placebo-controlled
trials have demonstrated the efﬁcacy of chondroitin sulfate for relief
of joint pain in patients with OA of the knee6e10; one of these meta-
analyses also noted a small signiﬁcant effect in favor of chondroitin
sulfate compared with placebo for structure modiﬁcation as
measured by a reduction in the rate of decline in joint space width9.
In 2008, we published the results of a systematic review and meta-
analysis of all available randomized, placebo-controlled trials to
determine the effects of the administration of orally administered
chondrotin sulfate on the rate of change in joint space width and
reported a small signiﬁcant structure-modifying effect for this
compound11. Herein we report the results of an updated meta-
analysis that includes data from two recently published studies12,13
and limits the pooling to studies of 2-year duration.Methods
Literature search
The search strategy for the original meta-analysis has been
described11. Brieﬂy, theMEDLINE databasewas search from January
1996 through October 2007 to identify all randomized controlledublished by Elsevier Ltd. All rights reserved.
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administered chondroitin sulfate to placebo. A total of 51 articles
were identiﬁed, including 31 review articles, six RCTs that reported
only symptomatic outcomes in patients with knee OA or structural
outcomes in patients with hand OA, ﬁve meta-analyses and four
editorials as well as ﬁve articles that reported data from three RCTs
of structural outcomes in patients with knee OA. These latter ﬁve
articles were selected for inclusion in the original meta-analysis,
along with data from one abstract presented at the 2006 annual
meeting of the American College of Rheumatology (ACR). Two of
these four trials were of 52 weeks duration and the other twowere
of 2-year duration. Since the publication of that manuscript, the
ﬁnal results of one of these latter trials that had been published
only in abstract form as well as the results of a third trial of 2-year
duration were published.
Trial selection
RCTs of 2-year duration that compared orally administered
chondroitin sulfate to placebo and reported structural outcomes in
the form of change in minimum joint space width were selected for
inclusion in this review. No language restriction was applied.
Data extraction
Data extracted included eligibility criteria, baseline patient
characteristics (age, gender, duration of OA), chondroitin sulfate
dose, baseline values for KellgreneLawrence grade and minimal
joint space width, if available, and change in minimum joint space
width at the end of trial by group. The data on change in minimum
joint space width were extracted by two persons.
Data analysis
The primary outcome measure was change in minimum joint
space width measured in mm. The I2 statistic was calculated to
describe the percent of total variation that is attributable to
heterogeneity rather than chance; values below 25% suggest low
while those greater than 75% suggest high between-trial hetero-
geneity14. Because there was no evidence of moderate or greater
heterogeneity, a standard ﬁxed effects meta-analysis was used to
pool data across the trials. The results were expressed in differences
in change in minimum joint space width between chondroitin
sulfate and placebo treated groups in mm as well as an effect size
calculated from the mean difference divided by the pooled stan-
dard deviation. All analyses were performed using RevMan version
5 (Cochrane Collaboration Information Management System;
www.cc-ims.net) by Dr Min Zhan.
Results
Study descriptions
The characteristics of the three studies included in the updated
meta-analysis are shown in Table I. All studies were of good quality
based on a Jadad score of 4 (range 0e5)15.Table I
Characteristics of trials included in update meta-analysis
Authors, year Dose of CS Duration N
Michel et al., 2005 800 mg once daily 24 months 3
Sawitzke et al., 2008 400 mg three times daily 24 months 2
Kahan et al., 2009 800 mg once daily 24 months 6
CS¼ chondroitin sulfate, PBO¼ placebo.Michel and colleagues randomized 300 patients aged 40e85
years who fulﬁlled ACR criteria for knee OA to receive either
chondroitin 4- and 6-sulfate 800 mg daily (Chondrosulf; IBSA,
Lugano, Switzerland) or placebo orally for 2 years16. The primary
objective was to determine whether chondroitin sulfate delayed or
halted structural changes in knee OA over 2 years. A single, partial
ﬂexion (w20) weight-bearing posteroanterior (PA) radiograph of
both knees was taken upon entry and at the end of the study or
time of dropout. Minimum joint space width was measured in both
knees using digitized ﬁlms by a single reader blinded to time
sequence using an image analysis computer according to a pub-
lished method17. The authors analyzed data from the more severely
affected compartment of the target (i.e., most symptomatic) knee
using a Wilcoxon test, and reported a signiﬁcant difference in favor
of the chondroitin sulfate group for change in minimum joint space
width in both an intention-to-treat analysis as well as sensitivity
analyses limited to 225 patients withminimum joint space of 1 mm
or greater at baseline and 219 patients who completed the 2-year
trial.
Sawtizke and colleagues reported results from the Glucosamine/
Chondroitin Arthritis Intervention Trial (GAIT) ancillary study to
assess structural changes in knee OA12. This ancillary study
included 662 patients who fulﬁlled ACR criteria for knee OA; for the
purposes of this meta-analysis we consider only those 257 patients
who were randomized to receive either chondroitin sulfate 400 mg
three times daily or placebo orally and were followed for up to 2
years. The primary aim of this prospective observational study of
GAIT enrollees was to determine whether the supplements could
have a structure-modifying effect in knee OA. A single, semiﬂexed,
weight-bearing PA radiograph of both knees was taken upon entry
and at the 12 and 24 months; the technique is that described by
Buckland-Wright as the MTP view18. Minimum joint space width
was measured in both knees using digitized ﬁlms by a single reader
blinded to time sequence using an image analysis computer
according to a publishedmethod18. The authors analyzed data from
the medial compartment of all affected knees with acceptable
radiographs; this included 116 knees in 71 patients randomized to
chondroitin sulfate and 113 knees in 70 patients randomized to
placebo. The difference in favor of the chondroitin sulfate group for
decline in mean joint space width, 0.059 mm, failed to reach
statistical signiﬁcance.
Kahan and colleagues reported results of a randomized, double-
blind, placebo-controlled study in 622 patients aged 45e80 years
who fulﬁlled ACR criteria for knee OA and were allocated to receive
either chondroitin 4- and 6-sulfate 800 mg daily (Genevrier Labo-
ratories, Sophia Antipolis, France, and IBSA, Pambio Noranco,
Switzerland) or placebo orally for 2 years13. The two primary
outcomes of this study were to determine whether chondroitin
sulfate could improve symptoms and delay structure progression
over 2 years in patients with knee OA. A single, partial ﬂexion
(w20e30) weight-bearing PA radiograph of the target knee was
taken upon entry and at 12, 18 and 24 months using the Lyon
Schuss technique with ﬂuoroscopy19. Minimum joint space width
was measured in the medial compartment using digitized ﬁlms by
a single reader blinded to time sequence using a digital image
analysis software. The authors reported a signiﬁcant difference ino. enrolled in CS and PBO groups Mean age (years) Women (%)
00 63 52
57 57 68
22 62 68
Table II
Meta-analysis of change in joint space width comparing patients allocated to chondroitin sulfate vs placebo
Authors, year CS PBO Mean difference (mm) (95% CI) Effect size (95% CI)
Mean (mm) SD (mm) Mean (mm) SD (mm)
Michel et al., 2005 0.045 0.48 0.07 0.56 0.12 (0.00, 0.23) 0.22 (0.01, 0.45)
Sawitzke et al., 2008 0.107* 0.68 0.166* 0.68 0.06 (0.17, 0.28) 0.09 (0.24, 0.42)
Kahan et al., 2009 0.07 0.03y 0.31 0.04y 0.14 (0.06, 0.21) 0.26 (0.11, 0.42)
Pooled analysis 0.13 (0.06, 0.19) 0.23 (0.11, 0.35)
CS¼ chondroitin sulfate, PBO¼ placebo, CI¼ conﬁdence intervals.
* Result adjusted for baseline joint space width, sex, pain score, disease duration, weight, KellgreneLawrence grade, study site and weeks of treatment.
y Standard error of the mean rather than standard deviation.
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space width in the intention-to-treat analysis. In addition, they
noted a signiﬁcant reduction in the proportion of subjects who had
radiographic progression deﬁned as a decline in minimum joint
space width of 0.25 mm or greater.Pooled effect on minimum joint space width
Results are shown in Table II.
There was no evidence of important heterogeneity between the
trials (I2¼ 0); hence, a ﬁxed effects model was used to pool the
data. The meta-analysis found that patients randomized to receive
orally administered chondroitin sulfate, compared to those
randomized to placebo, had a signiﬁcant reduction in the rate of
decline in joint space width over 2 years of 0.13 mm (95% CI 0.06,
0.19) (P¼ 0.0002) that corresponded to an effect size of 0.23 (95% CI
0.11, 0.35) (P¼ 0.0001).Discussion
The results of this meta-analysis suggest that chondrotin sulfate
at a dose of 800 mg orally once daily has a small but signiﬁcant
effect as a structure-modifying agent in patients with symptomatic
radiographic OA of the knee. These ﬁndings extend the results of
our previous meta-analysis11, and that conducted by Reichenbach
and colleagues9, and support the recommendations of the Osteo-
arthritis Research Society International for the use of chondroitin
sulfate as a structure-modifying agent in patients with OA of the
knee3.
The present meta-analysis has several strengths. It was based on
a systematic literature review performed for the original meta-
analysis11 with the inclusion of two newly published randomized
placebo-controlled trials. It was limited to studies of 2-year dura-
tion and included data on over 1000 patients with symptomatic
radiographic knee OA. There was no evidence of heterogeneity of
results across trials allowing the use of a ﬁxed effects model for
pooling data.
This meta-analysis is, however, limited by the data from the
individual trials. The individual trials included in this meta-analysis
varied in source of support, size, dosing schedule for chondroitin
sulfate, as well as the technique used to acquire the knee radio-
graphs. Both the studies reported by Michel and colleagues and
Kahan and colleagues were supported by industry while that
reported by Sawitzke and colleagues was supported by the National
Institutes of Health. The former two studies were statistically
powered for assessing the primary outcome of structure modiﬁ-
cation comparing chondroitin sulfate and placebo directly. The
structure modiﬁcation study of GAIT, on the other hand, was
designed and powered to allow comparison of structural differ-
ences across ﬁve treatment groups and only 662 of the 791
participants needed were enrolled. Furthermore, the amount of
missing data exceeded expectations resulting in only 55% statisticalpower to detect the pre-speciﬁed 0.2 mm difference between
active treatments and placebo.
While the source of chondroitin sulfate was the same across
studies (all chondroitin sulfate was supplied by Bioiberica SA
[Barcelona, Spain] either under license to IBSA or directly to the
GAIT investigators), the dosing of chondroitin sulfate varied
between studies. In the two industry supported studies, chon-
droitin sulfate was administered at a dose of 800 mg once daily,
while in GAIT it was administered at a dose of 400 mg three times
daily. It is possible that the higher drug concentrations obtained
with single daily dosing might have a different pharmacodynamic
effect as compared to the three times daily dosing schedule.
Despite the development of standardized protocols for obtain-
ing reproducible radiographs for the purpose of measuring joint
space width in the medial tibiofemoral compartment, there
continues to be controversy about the best method for use in trials
of structure-modifying agents20. Both the studies by Michel and
colleagues and Kahan and colleagues used the Lyon Schuss posi-
tion, one with ﬂuoroscopy, while GAIT used the Buckland-Wright
MTP view. All, however, used digitized ﬁlms with measurement of
minimum joint space width with computer-assisted techniques to
reduce the measurement error and increase the precision of the
measurement.
Overall, chondroitin sulfate at a dose of 800 mg orally once daily
appears to have a signiﬁcant but small effect of slowing the rate of
joint space narrowing over a period of 2 years in patients with
symptomatic radiographic knee OA. Hence, given the safety of
chondroitin sulfate, it appears reasonable to administer chon-
droitin sulfate to patients with symptomatic radiographic knee OA
for its possible structural beneﬁt3,21.
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